THCT (THC Therapeutics) ROCE % : 0.00% (As of Apr. 2024)

View and export this data going back to 2007. Start your Free Trial

What is THC Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. THC Therapeutics's annualized ROCE % for the quarter that ended in Apr. 2024 was 0.00%.

THC Therapeutics ROCE % Historical Data

The historical data trend for THC Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

THC Therapeutics ROCE % Chart

THC Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

ROCE %

Get a 7-Day Free Trial

-3,866.05

THC Therapeutics Quarterly Data
	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

THC Therapeutics ROCE % Calculation

THC Therapeutics's annualized ROCE % for the fiscal year that ended in Jul. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	-0.307	/	( ( (0.207 - 3.217)	+	(0.013 - 3.223) )	/ 2 )
	=	-0.307	/	( (-3.01	+	-3.21)	/ 2 )
	=	-0.307	/	-3.11
	=	9.87 %

THC Therapeutics's ROCE % of for the quarter that ended in Apr. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Apr. 2024 )		(Q: Jan. 2024 )		(Q: Apr. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Apr. 2024 )		(Q: Jan. 2024 )		(Q: Apr. 2024 )
	=	0.492	/	( ( (0.015 - 3.81)	+	(0.012 - 3.432) )	/ 2 )
	=	0.492	/	( ( -3.795	+	-3.42 )	/ 2 )
	=	0.492	/	-3.6075
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2024) EBIT data.

THC Therapeutics (OTCPK:THCT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

THC Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of THC Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

THC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » THC Therapeutics Inc (OTCPK:THCT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11700 W Charleston Boulevard, No. 73, Las Vegas, NV, USA, 89135

Website

https://thct.io

THC Therapeutics Inc is a United States-based company. It is focused on developing a sanitizing herb dryer, the dHydronator, which has been specifically designed for the drying and sanitizing i.e., reducing the bacterial count of freshly harvested cannabis, and other herbs, flowers, and tea leaves. The main function of the dHydronator is to accelerate the drying time of an herb while sanitizing it. The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis.

Executives

Hiro Tanaka	director, officer: Vice President	3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Smith Adrian J R	director, officer: Chair of the Board	119 SPRINGLINE DRIVE, VERO BEACH FL 32963
Jamie Mann	director, 10 percent owner, officer: CEO, CFO	3RD FLOOR, 207 REGENT STREET, LONDON X0 W1B 3HH
Eden Ho	director, officer: CEO	701 XUANG MI HU ROAD, XI YUAN, FUTIAN, SHENZHEN F4 XXXXXX